Roche to buy U.S. biotech firm Seragon for $725 million

ZURICH (Reuters) - Roche Holding AG said it will pay $725 million in cash to buy Seragon Pharmaceuticals, a privately-held biotech company that researches breast cancer treatments, and may pay up to another $1 billion based on certain milestones.

from Combined News for Reuters & Al Jazeera copy http://ift.tt/1o6pxS9